BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2026 4:34:33 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-05-08 06:02 |
|
Peer-Review Started |
|
2026-05-08 06:02 |
|
First Decision by Editorial Office Director |
|
2026-05-15 11:37 |
|
Return for Revision |
|
2026-05-15 11:37 |
|
Revised |
|
2026-05-18 10:53 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-06-01 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-06-01 09:09 |
|
Articles in Press |
|
2026-06-01 09:09 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-01 02:34 |
|
Publish the Manuscript Online |
|
2026-09-01 04:34 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Can upadacitinib dose escalation redefine treatment strategies in refractory inflammatory bowel disease?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Himanshu Agrawal and Nikhil Gupta |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nikhil Gupta, Department of Surgery, Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital, BKS Marg, Delhi 110001, India. nikhil_ms26@yahoo.co.in |
| Key Words |
Inflammatory bowel disease; Upadacitinib; Dose escalation; Janus kinase inhibitors; Treatment resistance; Personalized medicine; Ulcerative colitis; Crohn’s disease |
| Core Tip |
Upadacitinib dose escalation may provide symptomatic benefit and reduce corticosteroid dependence in selected patients with refractory inflammatory bowel disease who experience secondary loss of response. The findings of Ellington et al support a more flexible and individualized approach to therapeutic optimization while emphasizing the need for careful safety monitoring and prospective validation. |
| Publish Date |
2026-09-01 04:34 |
| Citation |
Agrawal H, Gupta N. Letter to the Editor: Can upadacitinib dose escalation redefine treatment strategies in refractory inflammatory bowel disease? World J Gastrointest Pharmacol Ther 2026; 17(3): 122912
|
| URL |
https://www.wjgnet.com/2150-5349/full/v17/i3/122912.htm |
| DOI |
https://doi.org/10.4292/wjgpt.122912 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
